Verastem, Inc. (VSTM)
| Market Cap | 335.30M |
| Revenue (ttm) | 91.63M |
| Net Income (ttm) | -86.64M |
| Shares Out | 169.51M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $2.03 |
| Previous Close | $1.96 |
| Change ($) | 0.07 |
| Change (%) | 3.32% |
| Day's Open | 1.93 |
| Day's Range | 1.87 - 2.07 |
| Day's Volume | 2,384,308 |
| 52-Week Range | 1.11 - 4.20 |
The biotech's chief medical officer has stepped down just two weeks after joining the company.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
Verastem has recently raised non-dilutive capital to bring two assets into phase 2 trials. The company's lead asset has the potential to address around 30% of all cancers and be combined with ...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today re...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients batt...
The biotech company reported second-quarter earnings and sold some drug development rights.
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients batt...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...
Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verastem: A Growth Story In The Biotechnology Sector
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients batt...
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.
Is (VSTM) Outperforming Other Medical Stocks This Year?
Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.
Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.
Investors are excited about an upcoming conference call to discuss clinical data from patients with KRAS-mutation positive tumors.
Verastem (VSTM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Verastem Oncology: An Undervalued KRAS Oncology Play
Healthcare bargain hunters can find good values in quality low-priced stocks.
Is (VSTM) Outperforming Other Medical Stocks This Year?
Verastem has been struggling lately, but the selling pressure may be coming to an end soon.
As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM).
Verastem: Still Bullish After Chugai Pharmaceutical Deal
Billionaire investor Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed earlier this week his firm established a new 14.91% stake in Verastem Inc.
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
Verastem: Earnings Beat And Executing 6-2-5 Plan Trigger Unjustified Sell-Off
Verastem, Inc. (VSTM) CEO Brian Stuglik on Q3 2019 Results - Earnings Call Transcript
Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem Oncology's share price continues to flatline as we approach the end of 2019. The market appears to have branded COPIKTRA's launch as a dud.
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
Verastem, Inc. (VSTM) CEO Brian Stuglik on Q2 2019 Results - Earnings Call Transcript
Verastem (VSTM) delivered earnings and revenue surprises of 2.04% and 41.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem announced they out-licensed COPIKTRA to Sanofi Develop and Commercialize in emerging markets. Verastem will receive an upfront payment of $5M, plus milestones and royalties.
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
About VSTM
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior s... [Read more...]
| Industry Biotechnology | IPO Date Jan 27, 2012 |
| CEO Brian Stuglik | Employees 135 |
| Stock Exchange NASDAQ | Ticker Symbol VSTM |
Financial Performance
In 2019, Verastem's revenue was $17.46 million, a decrease of -34.67% compared to the previous year's $26.72 million. Losses were -$149.21 million, 106.0% more than in 2018.
Analyst Forecasts
According to 3 analysts, the average rating for Verastem stock is "Buy." The 12-month stock price forecast is 3.83, which is an increase of 89.14% from the latest price.